thank you...I'll join as well. Enjoy following.

Actually, I sold Feb 14 calls, 14 strike for 1.15 the day the stock hit 8.40 a few Friday's ago. I took a wad of cash out and honestly never thought the stock would reach 14 even with positive data and partner prior to FDA approval. If it did...Oh well I make $12 a share and walk away with the majority of the kids colleges paid for. But...I think I'm right and will keep my 30K shares and the premium.

Congrats longs..today is a great day.

Great question and I look forward to reading answers.

I'm in at a cost basis of $4 with approx 30K shares accumulated over the last 4 years. I'm standing pat through data release as I think the odds of strong data is high. After that, that is where the risk elevates in my opinion because I don't trust FDA, Hedgies, Big P etc.. We should be in the 8-10 range and I'll likely sell a some shares or Jan 2015 calls (by then sb 14 for $2 premiums) to recover my inital investment and let the rest ride forever. Those funds will move to my continuing stake in MAKO which will double in the next 12-18 months.

I think there will be a strong partnership with some upfront money but balance contingent upon approval. If the data is good, I don't see them going it alone because the risk of not getting Afrezza and a competitor getting it is too high. Don't rule out Medtronic Diabetes. Someone will deal. If this happens, I see $12-14

Then it is up to the FDA where I feel anything could happen.

Not to mention the survival of the company to use portions of the profits to pursue long term growth and contribution through additional uses for technosphere and the cancer pipeline (the former I personally believe has tremendous potential and the latter I believe has little).

Nada...I'm a Regional Manager for a well respected medical device company and have been in the industry for some time including a 2 year stint in Hospital Administration. We gave our doctors less than 20 minutes and it was offset by NP and PA so it was more like 10. The pharma sales industry is crap now. All the good talented reps are begging me to hire them into devices so they can have a meaningful discussion with HCP's again. Or, they are going into other industries. The pharma companies are partially responsible for this, skimping on good training, hiring a lot of bimbo's with large boobs and spending hoard's of cash on lunches, dinners and "entertainment". Now with no ability to spend money on them and with their time constrained, older physicians no longer want to talk to a rep...especially those with little experience and can't debate without looking at their cliff notes. None of them really know their industry well anymore, move companies every 2 years or commit the time to be great consultants. I'm sure your father would agree with this. Even with devices, things are changing. We used to walk right by the pharma reps and into the procedure areas without hesitation. 10 years ago, I could walk right into the O/R locker room, change into scrubs and mask, and go right to my physician I was targeting and catch them before their case at the scrub sink and get a good 10 minute meeting. Many times I'd be invited into the case. Now, we have to make appointments and clear our access ahead of time which is 50/50 successful.

The only way to do it now, and it takes longer to seed the market, is to convince residents, fellows and midlevels. Their minds are open to education, they are accessible and spend more time with the patient now anyway. They also have the ability to influence those older decision makers in a way the medical sales reps no longer can. The second way is to go direct to consumer as you mention. Both take more time than they used to and why every drug launch today is slower and more expensive than expected before rapid adoption. MNKD cannot do this on their own. It will be way too expensive and dilutive. We also don't need a run of the mill sales force that markets to primary care...they are the least talented. I would love to see a Diabetes specific sales force like Medtronic Diabetes, Novo or Lilly Diabetes who know the disease state well and have the inroads to the right physicians (specialists) and can make access.

maybe someone raised this point already and maybe it is a dumb question....but is Primary Care the right Call Point to survey? Wouldn't it be the Endocrinologist who makes the decisions on c medical course of therapy for Diabetes?

Primary care deals with the sniffles...